FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference

FibroBiologics (Nasdaq: FBLG) announced that Founder and CEO Pete O’Heeron will present at the 9th Annual BFC Global Healthcare Business Development and Investment Conference on January 11, 2026 in San Francisco.

Rhea-AI Summary

FibroBiologics (Nasdaq: FBLG) announced that Founder and CEO Pete O’Heeron will present at the 9th Annual BFC Global Healthcare Business Development and Investment Conference on January 11, 2026 in San Francisco.

The company presentation is scheduled for 4:30 p.m. PT on Sunday, January 11, 2026 at The St. Regis. Interested parties may visit the company website or contact info@fibrobiologics.com for more information.

Argus Jan 6 session

+6.78% close to close Open Argus

Details

News Market Reaction – FBLG

On Jan 6, the day this news came out, FBLG closed 6.78% above the previous close.

Data tracked by StockTitan Argus for the Jan 6 session.

Key Figures

Patent portfolio: 270+ patents issued and pending Conference date: January 11, 2026 Presentation time: 4:30 p.m. PT

Patent portfolio

270+ patents issued and pending

Fibroblast-focused therapeutics and potential cures for chronic diseases

Conference date

January 11, 2026

9th Annual BFC Global Healthcare BD and Investment Conference

Presentation time

4:30 p.m. PT

Company presentation slot at conference

Historical Context

5 past events · Latest: Dec 31

5 events

1. Dec 31

   IND filing

   24h Move

   -7.0%

   Filed FDA IND to start Phase 1/2 trials of CYPS317 in psoriasis.

2. Dec 16

   Equity offering

   24h Move

   -8.4%

   Closed $1.7M registered direct and concurrent warrant private placement.

3. Dec 15

   Equity offering

   24h Move

   -33.1%

   Announced $1.7M registered direct offering with additional warrant proceeds potential.

4. Dec 10

   Patent filing

   24h Move

   +12.8%

   Filed U.S. patent for fibroblast-derived chondrocyte spheroid orthopedic platform.

5. Nov 26

   Debt payoff

   24h Move

   +1.5%

   Paid off Yorkville convertible notes while keeping SEPA capacity through 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

fibroblasts, fibroblast-derived materials

2 terms

fibroblasts medical

"using fibroblasts and fibroblast-derived materials, today announced that Founder"

Fibroblasts are common cells in connective tissue that manufacture the structural proteins and fibers—like collagen—that form and repair the body's scaffolding, helping wounds heal and tissues hold their shape. For investors, fibroblasts matter because they are frequent targets or tools in drug development, regenerative medicine and safety testing: changes in their behavior can signal whether a therapy will work, cause side effects or enable new medical products, much like a construction crew determines the strength and finish of a building.

fibroblast-derived materials medical

"therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials"

Materials produced or conditioned by fibroblasts—common connective‑tissue cells that secrete the structural proteins and other components tissues use as a scaffold. Investors should care because these biologically sourced materials are used in wound care, tissue engineering, cosmetic and regenerative products; their quality, scalability and regulatory path affect a product’s performance, manufacturing cost and commercial potential, much like the quality of bricks and mortar determines a building’s durability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the 9^th Annual BFC Global Healthcare Business Development and Investment Conference taking place January 11, 2026, at The St. Regis in San Francisco, California.

FibroBiologics will deliver a company presentation at 4:30 p.m. PT on Sunday, January 11.

For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will FibroBiologics (FBLG) present at the BFC Global Healthcare conference?

FibroBiologics will present on January 11, 2026 at 4:30 p.m. PT.

Who is presenting for FibroBiologics (FBLG) at the January 11, 2026 conference?

Pete O’Heeron, Founder and CEO, will deliver the company presentation.

Where is the 9th Annual BFC Global Healthcare conference taking place for FibroBiologics (FBLG)?

The conference is at The St. Regis in San Francisco, California.

How can investors access more information about FibroBiologics (FBLG) presentation on January 11, 2026?

Visit the company website or email info@fibrobiologics.com for presentation details.

Will FibroBiologics (FBLG) discuss clinical programs during the January 11, 2026 presentation?

The announcement notes the company is clinical-stage; specific presentation topics were not detailed in the notice.